Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

IL-13

  • Home
  • IL-13
IL-13 Inhibition with Cendakimab: A New Frontier in Eosinophilic Esophagitis Management
Posted inAllergy & Immunology Gastroenterology news

IL-13 Inhibition with Cendakimab: A New Frontier in Eosinophilic Esophagitis Management

Posted by MedXY By MedXY 12/31/2025
A Phase 3 trial demonstrates that cendakimab significantly reduces dysphagia days and improves histologic and endoscopic markers in patients with eosinophilic esophagitis, offering a targeted therapeutic approach for this chronic type 2 inflammatory condition.
Read More
Cendakimab: A Promising Therapeutic for Eosinophilic Esophagitis in Adolescents and Adults
Posted inGastroenterology news

Cendakimab: A Promising Therapeutic for Eosinophilic Esophagitis in Adolescents and Adults

Posted by MedXY By MedXY 09/26/2025
Cendakimab, a monoclonal antibody targeting IL-13, shows significant improvements in symptoms, histologic response, and endoscopic features in eosinophilic esophagitis, with a tolerable safety profile through 48 weeks.
Read More
  • Impact of Ring Pessary on Pelvic Anatomy in Upright Position: Insights from Prospective Upright MRI Study
  • Unveiling Posttraumatic Stress Trajectories Following Vaginal Delivery: Implications for Early Identification and Intervention
  • Optimizing Postpartum Care: Evaluating High-Dose Oxytocin Infusion to Reduce Blood Loss After Vaginal Delivery
  • Strategic Sequencing of Systemic Therapies in Advanced Hepatocellular Carcinoma: Beyond the Second Line
  • Functional Anti-preS1 Antibody Responses and Their Role in Viral Control in Chronic Hepatitis B
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized trial risk stratification semaglutide SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in